Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 6, 2006, Pages 657-668

  Jucaite, Aurelija ^a   Odano, Ikuo ^b   Olsson, Hans ^a   Pauli, Stefan ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Dopamine transporter; Human; Kinetic modelling; PET; Substantia nigra

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROPENYL) 2BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING AFFINITY; BINDING KINETICS; BRAIN TISSUE; CEREBELLUM; CORPUS STRIATUM; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; MALE; MESENCEPHALON; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RADIOACTIVITY;

ADULT; BRAIN; COMPUTER SIMULATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 33744912786     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0027-9     Document Type: Article

References (52)

1. Gulley JM, Zahniser NR. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. Eur J Pharmacol 2003;31(479):139-152
2. Antonini A, Moresco RM, Gobbo C, De Notaris R, Panzacchi A, Barone P, et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci 2000;22:47-48
3. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997;120:503-514
4. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvalahti E, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115-120
5. 99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000;27:1518-1524
6. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with ADHD; association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005;57(3):229-238
7. Volkow ND, Wang GJ, Fowler JS, Logan J, Francheschi D, Maynard L, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and increase in the extracellular dopamine: therapeutic implications. Synapse 2002;43:181-187
8. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted-2- carbomethoxy-3-(4'-iodophenyl)nortropane and N-(3-iodoprop-2E-enyl)-2- carbomethoxy-3-(3',4'-disubstituted phenyl)nortropane. New affinity and selectivity compounds for the dopamine transporter. J Med Chem 1997;40:1366-1372
9. 125I]PE2I. Neuroimage 1999;9:108-116
10. 11C]PE2I - a highly selective radioligand for PET-examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220-1230
11. 11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab 1989;9:398-409
12. Wong D, Gjedde A, Wagner H Jr. Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986;6:137-146
13. Mintun M, Raichle M, Kilbourn M, Wooten G, Welch M. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227
14. Huang S, Barrio J, Phelps M. Neuroreceptor assay with positron emission tomography. Equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1986;6:515-521
15. Caceci MS, Cacheris WP. Fitting curves to data, the Simplex algorithm in the answer. BYTE 1984;9:340-362
16. Perlmutter JS, Larson KB, Raichle ME, Markham J, Mintun MA, Kilbourn MR, et al. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 1986;6:154-169
17. 2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989;9:696-708
18. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-744
19. 11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab 1995;15:284-300
20. Farde L, Ito H, Swahn CG, Pike VW, Halldin C. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J Nucl Med 1998;39:1965-1971
21. 11C]raclopride studies. J Cereb Blood Flow Metab 1996;16:42-52
22. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-723
23. Schwartz G. Estimating the dimension of a model. Ann Stat 1978;6:461-564
24. Hawkins R, Phelps M, Huand S-C. Effects of temporal sampling, glucose metabolic rates, and disruptions of the blood-brain barrier on the FDG model with and without a vascular compartment. Studies in human brain tumours with PET. J Cereb Blood Flow Metab 1986;6:170-183
25. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747
26. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996;4:153-155
27. Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widen L. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 1981;5:136-141
28. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994;18:108-110
29. Eriksson L, Holte S, Bohm C, Kesselberg M, Hovander B. Automated blood sampling systems for positron emission tomography. IEEE Trans Nucl Sci 1988;35:703-707
30. Drebin RA, Carpenter L, Hanrahan P. Volume rendering. Comput Graph 1988;22:65-74
31. Toga AW. Three dimentional neuro imaging. New York: Raven Press; 1990
32. Pauli S, Sedvall G. Three-dimensional visualization of the benzodiazepine receptor population within a living human brain using PET and MRI. Eur Arch Psychiatry Clin Neurosci 1997;247:61-70
33. Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage 2004;22:794-803
34. Tupala E, Kuikka JT, Hall H, Bergstrom K, Sarkioja T, Rasanen P, et al. Measurement of the striatal dopamine transporter density and heterogeneity in type 1 alcoholics using human whole hemisphere autoradiography. Neuroimage 2001;14:87-94
35. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999;21(409): 38-56
36. Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands - state of art and new trends. Q J Nucl Med 2001;45:139-152
37. Laruelle M, Slifstein M, Huang Y. Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 2002;27:287-299
38. Chalon S, Emond P, Garreau L, Frangin Y, Mauclaire L, Guilloteau D, et al. Characterisation of the cocaine derivative PE2I, a high specific marker for imaging the dopamine transporter by SPECT. Eur J Nucl Med 1997;24:880
39. Gu XH, Zong R, Kula NS, Baldessarini RJ, Neumeyer JL. Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: potential positron emission tomography (PET) imaging agents for the dopamine transporter. Bioorg Med Chem Lett 2001;11:3049-3053
40. 11C] beta-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997;24:621-627
41. Karlsson P, Sedvall G, Halldin C, Swahn CG, Farde L. Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man. Psychopharmacology (Berl) 1995;121:300-308
42. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231(4735):258- 261
43. Madras BK, Gracz LM, Fahey MA, Elmaleh D, Meltzer PC, Liang AY, et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in post-mortem normal and Parkinson's diseased brain. Synapse 1998;29:116-127
44. Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR. Eur J Neurosci 2003;18:2668-2672
45. 11C-PE2I, a high selective ligand for PET examination of the dopamine transporter. J Nucl Med 2005;346:347
46. 11C]raclopride in man. Synapse 1995;10:200-208
47. 123I]PE2I binding to dopamine transporters with SPET. Eur J Nucl Med Mol Imaging 2002;29:623-631
48. 11C] FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999;19(10):1164-1173
49. Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 2004;22(2):794-803
50. Slifstein M, Laruelle M. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 2000;41:2083-2088
51. Moore RY. Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. Parkinsonism Relat Disord Suppl 2003;2:S65-S71
52. 18F]fluoro-L-dopa. J Cereb Blood Flow Metab 2001;21:782-792